Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc.

Ontario Industry Updates
Written By Viktoriya Shabat
1280px-Boston_Scientific_Logo.svg.png

Boston Scientific Corporation announced, on October 6, that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments.

Baylis_Logotype_black.png

The acquisition will expand the Boston Scientific electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG® and VersaCross® Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access. These platforms have advanced transseptal puncture and are clinically proven to enhance safety, efficacy and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart, such as atrial fibrillation ablation, left atrial appendage closure (LAAC) and mitral valve interventions.

Viktoriya Shabat
Previous

Highmark Interactive Announces Collaboration with Mayo Clinic to Assess Impact of 'Long COVID' on Cognitive Function
Next

OBIO Announces Expansion of Early Adopter Health Network Partnerships